Objective: Low-molecular-weight heparin (LMWH) is used during pregnancy in women diagnosed with thrombophilia for prevention of thromboembolic events and prevention of recurrent pregnancy loss. Prophylactic dosing does not always achieve target anti-FXa levels of 0.2-0.6 IU/ml. We aimed to determine if anti-FXa levels, measured in the first trimester, have an influence on pregnancy outcome.
Material And Methods: Eighty-one first-trimester women with a history of adverse pregnancy outcomes under LMWH therapy during pregnancy were enrolled in this study. Anti-FXa levels were measured in the first trimester, and fetal and maternal outcomes were recorded.
Results: The mean age of women was 28±4 (19-40) and mean anti-FXa level 0.44±0.93 IU/ml. No bleeding or clotting complications were associated with LMWH administration. Anti-FXa levels did not have a relationship with gestational age at birth, fetal weight, type of delivery, cesarean indications, postpartum bleeding, APGAR scores, or admission to the neonatal intensive care unit (p>0.005). Anti-FXa levels were not correlated with live birth rates.
Conclusion: Anti-FXa levels did not have an influence on pregnancy and fetal outcomes. The effect of LMWH on pregnancy outcomes may not be due to anticoagulant activity but other mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1130-2017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Efficacy of Andexanet Alfa for the Reversal of Factor Xa Inhibitors Is Not Influenced by Hemodilution with Different Volume Expanders.
J Clin Med
November 2024
Department of Anesthesiology, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Andexanet alfa is a specific antidote for factor Xa (FXa) inhibitors. It is licensed to treat patients under FXa inhibitor therapy with life-threatening bleeding. Concomitantly, volume expanders are used to compensate for blood loss and maintain circulation.
View Article and Find Full Text PDFEstablishment of an Integrated Population Pharmacokinetic/Pharmacodynamics Model of Apixaban in Chinese Healthy Population Adjusting for Key Genetic Variants.
Curr Pharm Des
October 2024
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Article Synopsis
- The study aims to enhance the understanding of how genetic and nongenetic factors influence the pharmacokinetics and pharmacodynamics (PK/PD) of apixaban to enable personalized medication prescriptions for future patients.* -
- Researchers created an integrated PK/PD model based on data from 181 healthy Chinese volunteers, analyzing various biological markers and genetic factors, with a total of 2877 observations used for the modeling process.* -
- The final PK model indicates key variables like clearance rate and absorption rate, while the PD model successfully simulates the effects of apixaban on relevant blood markers, supporting the idea that individual dosing can be tailored effectively.*
Efficacy and safety of antithrombin supplementation in neonates and infants on a continuous heparin infusion.
Res Pract Thromb Haemost
January 2024
Division of Newborn Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Background: Antithrombin (AT) is a natural anticoagulant and potent inhibitor of several coagulation proteins, including activated factor X (FXa) and FIIa. The therapeutic activity of heparin depends on the presence of AT. Levels of plasma AT are low in neonates and young infants compared to those in adults.
View Article and Find Full Text PDFClot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban.
Thromb J
March 2024
Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Background: There are situations where information about the anticoagulant effects of Rivaroxaban could be clinically useful. Methods for measuring Rivaroxaban concentrations are not available at all medical laboratories while the test MRX PT DOAC for measuring the functional effects of Rivaroxaban, in CTR (Clot Time Ratio), can be made available around the clock. The objectives of this study were to investigate CTR in trough and peak samples during Rivaroxaban treatment of atrial fibrillation and to correlate the findings to bleeding episodes.
View Article and Find Full Text PDFLarge variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients.
BMC Pharmacol Toxicol
February 2024
Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
Purpose: Critically ill COVID-19 and non-COVID-19 patients receive thromboprophylaxis with the LMWH nadroparin. Whether a standard dosage is adequate in attaining the target anti-FXa levels (0.20-0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!